单唾液酸四己糖神经节苷脂治疗缺氧缺血性脑病的临床疗效

Clinical effect of monosialotetrahexose ganglioside in the treatment of hypoxic ischemic encephalopathy

目的探讨单唾液酸四己糖神经节苷脂治疗缺氧缺血性脑病的临床疗效。方法选取2019年5月至2020年5月本院收治的74例缺氧缺血性脑病患者作为研究对象,根据入院时间不同分为对照组(2019年5—11月)与观察组(2019年12月至2020年5月),每组37例。对照组给予常规治疗,观察组在对照组基础上给予单唾液酸四己糖神经节苷脂治疗,比较两组治疗前后血清学指标[胰岛素生长因子-1(IGF-1)、脂联素(APN)、基质金属蛋白酶9(MMP-9)、血清可溶性细胞间黏附分子-1(sICAM-1)]、美国国立卫生研究院卒中量表(NIHSS)评分和临床疗效。结果治疗前,两组IGF-1、APN、MMP-9、sICAM-1水平比较差异无统计学意义;治疗后,两组IGF-1、APN水平均高于治疗前,MMP-9、sICAM-1水平均低于治疗前,且观察组IGF-1、APN水平均高于对照组,MMP-9、sICAM-1水平均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组NIHSS评分比较差异无统计学意义;治疗后,两组NIHSS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为89.19%,高于对照组的67.57%,差异有统计学意义(P<0.05)。结论单唾液酸四己糖神经节苷脂治疗缺氧缺血性脑病效果确切,可缩小患者脑血肿体积,优化血清学指标,减轻脑损伤程度,提高疗效。

Objective To investigate the clinical efficacy of monosialotetrahexose ganglioside in the treatment of hypoxic ischemic encephalopathy.Methods Atotal of 74 patients with hypoxic ischemic encephalopathy admitted to our hospital from May 2019 to May 2020 were selected as the research subjects,and they were divided into control group(from May to November 2019)and observation group(from December 2019 to May 2020)according to different admission times,with 37 cases in each group.The control group was given conventional treatment,and the observation group was given monosialotetrahexose ganglioside on the basis of the control group,the serological indexes(insulin growth factor-1[IGF-1],adiponectin[APN],matrix metalloproteinase-9[MMP-9],serum soluble intercellular adhesion molecule-1[sICAM-1]),National Institutes of Health stroke scale(NIHSS)score before and after treatment and clinical efficacy were compared between the two groups.Results Before treatment,there was no significant difference in IGF-1,APN,MMP-9 and sICAM-1 levels between the two groups;after treatment,the levels of IGF-1 andAPN of the two groups were higher than before treatment,the levels of MMP-9 and sICAM-1 were lower than before treatment,the levels of IGF-1 andAPN in the observation group were higher than those in the control group,MMP-9 and sICAM-1 levels were lower than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in NIHSS score between the two groups;after treatment,NIHSS scores of the two groups were lower than those before treatment,and observation groupwas lower than control group,the differences were statistically significant(P<0.05).The total effective rate in the observation group was 89.19%,which was higher than 67.57%in the control group,and the difference was statistically significant(P<0.05).Conclusion Monosialotetrahexose ganglioside is effective in the treatment of hypoxic ischemic encephalopathy,it can reduce the volume of cerebellar hematoma,optimize the serological index,reduce the degree of brain injury and improve the curative effect.